Backhaus, P. http://orcid.org/0000-0003-4164-4104
Gierse, F.
Burg, M. C.
Büther, F.
Asmus, I.
Dorten, P.
Cufe, J.
Roll, W.
Neri, D.
Cazzamalli, S.
Millul, J.
Mock, J.
Galbiati, A.
Zana, A.
Schäfers, K. P.
Hermann, S.
Weckesser, M.
Tio, J.
Wagner, S.
Breyholz, H.-J.
Schäfers, M.
Funding for this research was provided by:
Universitätsklinikum Münster
Article History
Received: 13 October 2021
Accepted: 6 December 2021
First Online: 27 December 2021
Declarations
:
: Analysis of clinical data has been approved by the Ethics Committee of the Medical Association of Westphalia-Lippe and the Medical Faculty of the University of Münster (Az. 2021-408-f-S).
: All patients gave written informed consent for <sup>68</sup>Ga-OncoFAP-PET/CT and/or PET/MRI imaging and retrospective scientific analysis.
: Not necessary, as no potential identifying details/images are published.
: The Department of Nuclear Medicine of the University Hospital of Münster received an institutional research grant from Philochem AG. JM, SC, JM, AG, and AZ are employees of Philochem AG, the company that owns and has patented OncoFAP. All the other authors declare no competing interests.